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PURPOSE. Substantial progress has been made in identifying susceptibility variants for AMD in
European populations; however, few studies have been conducted to understand the role
these variants play in AMD risk in diverse populations. The present study aims to examine
AMD risk across diverse populations in known and suspected AMD complement factor and
lipid-related loci.
METHODS. Targeted genotyping was performed across study sites for AMD and lipid trait-
associated single nucleotide polymorphism (SNPs). Genetic association tests were performed
at individual sites and then meta-analyzed using logistic regression assuming an additive
genetic model stratified by self-described race/ethnicity. Participants included cases with early
or late AMD and controls with no signs of AMD as determined by fundus photography.
Populations included in this study were European Americans, African Americans, Mexican
Americans, and Singaporeans from the Population Architecture using Genomics and
Epidemiology (PAGE) study.
RESULTS. Index variants of AMD, rs1061170 (CFH) and rs10490924 (ARMS2), were associated
with AMD at P ¼ 3.05 3 108 and P ¼ 6.36 3 106, respectively, in European Americans. In
general, none of the major AMD index variants generalized to our non-European populations
with the exception of rs10490924 in Mexican Americans at an uncorrected P value < 0.05.
Four lipid-associated SNPS (LPL rs328, TRIB1 rs6987702, CETP rs1800775, and KCTD10/
MVK rs2338104) were associated with AMD in African Americans and Mexican Americans (P
< 0.05), but these associations did not survive strict corrections for multiple testing.
CONCLUSIONS. While most associations did not generalize in the non-European populations,
variants within lipid-related genes were found to be associated with AMD. This study
highlights the need for larger well-powered studies in non-European populations.
Keywords: age-related macular degeneration, CFH Y402H, ARMS2 A69S, PAGE Study, genetic
epidemiology
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Age-related macular degeneration is the third leading causeof visual impairment worldwide,1 commonly affecting
seniors more than any other form of blindness. Unlike many
other common, complex disorders, substantial progress has
been made in identifying susceptibility variants for AMD. The
most widely replicated loci are complement factor H (CFH)
and the age-related maculopathy susceptibility-2 (ARMS2)/HtrA
serine peptidase 1 (HTRA1) complex.2–6 Multiple polymor-
phisms within the chromosome 10q26 region have been
proposed as the functional variation including ARMS2 A69S,
the HTRA1 promoter variant rs11200638 adjacent to
ARMS2,7,8 and a complex insertion/deletion variant in the
untranslated region (UTR) of ARMS2.9,10
Before the successful identification of genetic factors,
studies of epidemiological risk variables for AMD have
consistently found that particular demographic groups expe-
rience a greater burden of disease. Those at an increased risk
are women, older individuals, smokers, and individuals of
European descent.11–13 Prevalence rates of any AMD vary by
race and ethnicity with non-Hispanic whites (7.3%) experienc-
ing a higher burden than non-Hispanic blacks (2.4%), and
Mexican Americans (5.1%) in a study of the U.S. population
over the age of 40.14 The prevalence of AMD in Asian
populations is similar to that observed in European-descent
populations at approximately 6.8%.15 Some studies have
identified blood pressure, body mass index, physical activity,
and lipids as environmental modifiers of AMD risk, but these
findings are not universal.12,16,17 Cigarette smoking is a
significant environmental risk factor and has been shown to
modify the effect of ARMS2 A69S in some,18,19 but not all,20,21
studies. Individuals with bilateral AMD were found to be more
likely to have been heavy smokers (odds ratio [OR]¼ 5.1) than
with those who presented with unilateral AMD.22
A substantial body of research has implicated lipid levels as
a major risk factor in AMD, particularly high-density lipoprotein
(HDL) cholesterol, though the relationship between serum
HDL levels and AMD risk is inconsistent.23,24 Reynolds and
colleagues23 found a protective effect of higher HDL levels
against AMD. Conversely, the Rotterdam Study found that
higher levels of HDL increased the risk (OR¼1.20 per standard
deviation increase) of incident AMD.24 The exact role that
lipids play in AMD pathology is still unknown, but new insights
may be garnered from genetic association studies that have
found evidence of a correlation between lipid-trait genes and
AMD risk. Recently, a meta-analysis of over 17,000 advanced
AMD cases confirmed the findings of variants previously
associated with HDL cholesterol on susceptibility to AMD that
had been observed in two previous genome-wide association
studies (GWASs).25–27
Many of these associations were first discovered and
described in European-descent case-control populations. Thus,
more data are needed to clarify the role of these variants
individually on disease susceptibility, in combination with each
other and other risk factors for AMD, in population-based
samples, and in other racial/ethnic groups. A major goal of the
Population Architecture Using Genomics and Epidemiology
(PAGE) study is to describe the underlying genetic architecture




Participants from three PAGE study sites are included in this
study: the Atherosclerosis Risk in Communities (ARIC) study,
the Cardiovascular Health Study (CHS), and Epidemiologic
Architecture for Genes Linked to Environment (EAGLE) study
accessing the Third National Health and Nutrition Examination
Survey (NHANES III). In addition to data from the PAGE study
sites, additional data are presented from the Singapore
Prospective Study Programme (SP2) and the Singapore Malay
Eye Study (SiMES). Brief descriptions of each study are given in
Table 1. The original phenotypic focus of each study varies
from cardiovascular traits (ARIC and CHS), type 2 diabetes and
cardiovascular diseases (SP2), ocular traits (SiMES), and a
representative sample of the United States regardless of health
status (EAGLE).
The ARIC study is a population-based cohort study that
included 15,792 women and men aged between 45 and 64
years at recruitment in 1987 through 1989.28 The participants
were selected by probability sampling from four US commu-
nities: suburbs of Minneapolis, Minnesota; Washington County,
Maryland; Jackson, Mississippi; and Forsyth County, North
Carolina. Retinal photographs were taken at the third visit,
allowing inclusion of a subset of participants in this study of
AMD.29 A digitized, 458 color fundus photograph was taken of
one eye from participants aged between 48 and 72 years. We
graded AMD according to a modified version of the Wisconsin
Age-Related Maculopathy Grading System.30 Current smoking
TABLE 1. Description of Study Participants, by Study Site
ARIC CHS EAGLE
European American African American European American African American European American
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
n 289 3128 34 582 351 1918 31 381 190 664
Age 65.1 (3.1) 64.3 (3.0) 63.9 (3.1) 64.0 (3.1) 72.4 (4.6) 70.7 (4.2) 72.4 (4.4) 71.5 (4.7) 76.4 (8.1) 71.2 (7.5)
Body mass











210.0 (36.7) 213 (39.0) 198.9 (29.2) 210.1 (35.9) 230.0 (79.5) 228.6 (76.0)
Fasting HDL
cholesterol 50.0 (16.5) 51.5 (18.4) 53.1 (20.0) 55.4 (18.1) 56.0 (16.6) 54.3 (15.4) 59.4 (14.4) 58.8 (15.0) 52.7 (15.5) 66.7 (113.9)
Female, % 49.1 51.3 44.1 63.6 57.0 60.0 74.2 65.1 66.8 54.5
Current
smokers, % 61.6 60.1 58.8 50.5 9.6 8.7 12.9 13.3 44.2 52.0
Means and SDs are given unless otherwise noted.
* Study site did not collect fasting data; statistics are shown for nonfasting data.
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was defined by ‘‘Do you now smoke cigarettes’’? After the
institutional review board at every participating university
approved the ARIC Study protocol, written informed consent
was obtained from each participant.
The CHS study is a population-based longitudinal study of
risk factors for cardiovascular disease in adults aged 65 years or
older, recruited at four field centers (Forsyth County, North
Carolina; Sacramento County, California; Washington County,
Maryland; Pittsburgh, Pennsylvania).31 Overall, 5201 predom-
inantly white individuals were recruited from 1989 to 1990
from random samples of Medicare eligibility lists, followed by
an additional 687 African Americans recruited from 1992 to
1993. Starting in 1989, participants underwent standardized
clinical exams at enrollment, which included blood pressure,
lipid profiles, echocardiography of the heart, carotid ultra-
sound, cranial magnetic-resonance imaging (MRI), and fundus
photography. Retinal photographs were taken with a 458
nonmydriatic camera of one randomly selected eye from
participants.29,32 The status of AMD was graded according to
the modified Wisconsin Age-Related Maculopathy classification
scheme.30 The main outcomes are coronary heart disease,
angina, heart failure, stroke, transient ischemic attack, claudi-
cation, and mortality. Current smoking status was self-reported
at baseline.
The National Health and Nutrition Examination Surveys
(NHANES), conducted by the National Center for Health
Statistics at the Centers for Disease Control and Prevention
(CDC), are US population–based, cross-sectional surveys
collected without regard to health status and include detailed
demographic, health, lifestyle, laboratory, clinical, and physical
examination data for study participants. The National Health
and Nutrition Examination Surveys was conducted in two
phases between 1988 and 1994, and DNA samples were
collected in the second phase (1991–1994).33,34 Genetic
NHANES III consists of 7159 DNA samples, and the method
of collection has been previously described.35,36 We used study
participant data from NHANES III, of which 3131 had available
fundus photographs and laboratory measurements of serum
cotinine (ng/mL). Participants aged older than 40 years were
selected to have a nonstereoscopic, 458 color fundus photo-
graph taken of one randomly selected eye. Age-related macular
degeneration was graded according to the Wisconsin Age-
Related Maculopathy Grading System.30 Current smokers were
defined as those who answered ‘‘yes’’ to the question ‘‘Do you
smoke cigarettes now?’’ or those with cotinine levels > 15 ng/
mL. All procedures were approved by the CDC Ethics Review
Board and written informed consent was obtained from all
participants. Because no identifying information is available to
the investigators, Vanderbilt University’s Institutional Review
Board determined that this study met the criteria of ‘‘nonhu-
man subjects.’’
The Singapore Prospective Study Programme is a popula-
tion-based cohort consisting of Singaporean Chinese partici-
pants aged between 40 and 80 years.37 Initially, subjects (n ¼
10,747) were invited from four population-based cross-
sectional surveys conducted in Singapore (1982–1998) to
participate in a repeat examination from 2004 to 2007.38–41
Participants who were successfully re-contacted and complet-
ed a questionnaire (n¼ 7744; 76.8% response rate) were then
invited to attend a clinic health examination that included
physicals and ocular assessment, retinal photography, and
collection of biologic specimens, of which 5163 (66.7% of
those who completed the questionnaire or 51.2% of all eligible
subjects) attended. Retinal photographs were taken of both
eyes with a 458 digital retinal camera and are available for 4110
participants.42 We graded AMD according to the Wisconsin
Age-Related Maculopathy Grading System.43 A structured
interviewer-administered questionnaire was used to collect
information about smoking status. Current smoking status was
self-reported.
The Singapore Malay Eye Study is a population-based cross-
sectional study of urban Singaporean Malay adults, conducted
to assess prevalence, risk factors, and the public health impact
of common age related eye diseases.44 An age-stratified (by 10-
year age group) random sample of the Malay population
residing in 15 residential districts in Southwestern Singapore
age 40 to 80 years was drawn from the computer-generated
random list of 16,069 Malay names provided by the Ministry of
Home Affairs. Of 4168 eligible participants, 3280 (overall
response rate 78.7%) participated in the study, conducted from
August 2004 through June 2006. Retinal photographs were
taken of both eyes in participants with a digital retinal camera
and AMD was graded according to the Wisconsin Age-Related
Maculopathy Grading System.45 A questionnaire was used to
collect information about smoking status, with participants
self-reporting current smoking status.
This research adhered to the tenets of the Declaration of
Helsinki. Approval for the study was obtained from the
appropriate institutional review boards at all participating
institutions, and all study participants gave informed consent
TABLE 1. Extended
EAGLE SP2 SiMES
African American Mexican American Asian Asian
Cases Controls Cases Controls Cases Controls Cases Controls
30 209 47 270 21 206 107 863
70.2 (7.5) 68.5 (6.9) 69.3 (7.0) 67.2 (6.3) 69.3 (5.3) 67.1 (4.9) 71.3 (5.4) 69.0 (5.6)
31.0 (6.3) 28.2 (6.2) 28.6 (5.3) 28.4 (5.3) 21.3(3.3) 23.2 (3.1) 25.5 (5.8) 26.2 (5.0)
235.7 (56.2) 229.9 (104.5) 256.6 (145.9) 222.1 (70.9) 197.2 (30.9) 208.8 (34.8) 220.4 (42.5)* 224.2 (46.4)*
63.2 (19.5) 71.2 (116.8) 84.6 (180.0) 53.9 (71.6) 54.1 (11.6) 54.1 (11.6) 54.1 (11.6)* 50.2 (11.6)*
60.0 47.4 44.7 44.1 19.05 46.60 29.91 51.68
50.0 58.9 53.2 54.8 38.10 22.82 48.57 36.74
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where appropriate. All work for studies conducted in the
United States were HIPAA-compliant.
AMD Phenotype Definition
At all study sites, fundus photographs were graded according
to a modified version of the Wisconsin Age-related Maculop-
athy Scale.30 Early AMD cases were aged at least 60 years and
included participants with: soft drusen, depigmentation of the
retinal pigment epithelium in the presence of soft and/or hard
drusen, or hyperpigmentation in the presence of soft and/or
hard drusen. Late AMD included individuals aged 60 years and
older with geographic atrophy, subretinal hemorrhage, subret-
inal fibrous scarring, or sensory serous subretinal detachments.
Controls were aged at least 60 years with gradable retinal
photographs showing an absence of hallmark AMD features.
Demographic characteristics of the study participants are
presented in Table 1.
Genotyping
As part of the larger PAGE study, SNPs were selected for
genotyping based on previous GWAS and candidate gene
studies for a variety of common human diseases and traits
including AMD; lipid-traits (HDL cholesterol, low density
lipoprotein cholesterol, and triglycerides); body mass index/
obesity; type 2 diabetes; hypertension; and inflammation (C-
reactive protein), to name a few. For this study, we included
both AMD and lipid-trait associated SNPs reported in genome-
wide association studies or the National Human Genome
Research Institute’s GWAS catalog as of 2009.46 A total of 57
SNPs were selected for analysis and included the two primary
AMD variants (CFH rs1061170 and ARMS2 rs10490924); other
variants involved in the complement system pathway (CFH
rs800292, rs1065489, rs3753394, rs3766404, rs6677604,
rs800292; CFI rs10033900, rs11726949; C2 rs547154), and
variants associated with lipid-related traits (Supplementary
Table S1). As described in Matise et al.,47 genotyping in the
PAGE Study was performed at each PAGE study site indepen-
dently using a variety of genotyping assays and platforms. Not
all 57 SNPs were genotyped in each study site (Supplementary
Table S1). For quality control, all PAGE study sites genotyped
360 DNA samples (CEU, YRI, CHB, JPN, and MEX) from the
International HapMap Project, including 77 parent-child
trios.47
In ARIC, the CFH Y402H variant (rs1061170) was
previously genotyped in a candidate gene study using the
TaqMan assay and polymerase chain reaction amplification
(Applied Biosystems, Foster City, CA, USA).48 Genotypes were
called using the ABI 7900HT and the sequence detection
system software (ABI PRISM 7700; Applied Biosystems).
Genotyping of DNA for the ARMS2 A69S variant
(rs10490924) was part of a GWAS using a commercial array
(GeneChip SNP Array 6.0; Affymetrix, Inc., Santa Clara, CA,
USA).49 The high density lipoprotein–associated SNPs used in
this study were genotyped as previously described.50
In the Cardiovascular Health Study, CFH Y402H and ARMS2
were not genotyped. Genotyping data for other variants were
obtained from two sources. First, SNP genotyping was
conducted in the Houston central lab using TaqMan (see
details above for ARIC). The second source of genotyping data
from CHS was performed at the General Clinical Research
Center’s phenotyping/genotyping Laboratory at Cedars-Sinai
using a beadchip system (Illumina 370CNV BeadChip; Illumina,
Inc., San Diego, CA, USA). Genotypes were called using
commercial software (Illumina BeadStudio; Illumina, Inc.).49
In Epidemiologic Architecture for Genes Linked to Environ-
ment, CFH Y402H (rs1061170) and ARMS2 A69S (rs10490924)
were genotyped by the Center for Human Genetics Research
DNA Resources Core in NHANES III using a commercial assay
system (Sequenom iPLEX Gold; Illumina, Inc.) according to the
manufacturer’s instructions. Blinded duplicates were geno-
typed as required by CDC, and both SNPs passed quality
control metrics required by CDC. The following lipid trait-
associated SNP data were accessed from existing genotype data
in Genetic NHANES: rs3890182 (ABCA1), rs3135506 (APOA5),
rs1800775 (CETP), rs1323432 (GRIN3A), rs1800588 (LIPC),
and rs328 (LPL).51 The remaining lipid trait-associated SNPs
were genotyped using commercial assay system (Sequenom or
Illumina BeadXpress; Illumina, Inc.). All genotype data
reported here were deposited into the NHANES III Genetic
database and are available for secondary analysis through CDC.
In Singapore Prospective Study Programme, Chinese
samples were previously genotyped as controls for a type 2
diabetes case control study which used beadchip kits (Illumina
HumanHap 610 Quad or 1MDuo-v3 BeadChips; Illumina, Inc.)
as part of a psoriasis case control study which used a
commercial beadchip kit (Illumina HumanHap 550 BeadChip;
Illumina, Inc.). Genotyping details have been published
elsewhere.52
Genotyping methods with SiMES followed those of the SP2
cohort as previously described.53
Genotyping for any given SNP, in a particular population,
was not always available across all study sites. Therefore, we
provide the following maximum and minimum ranges that
include cases and controls for genotyping data by population:
European Americans (n¼ 4546–6540), African Americans (n¼
796–1267), Mexican Americans (n¼275–317), and Asians (n¼
972–1197).
Statistical Analysis
Each study site performed tests of association locally using a
common analysis protocol prior to meta-analysis. Early and late
cases of AMD were combined for analyses to increase power.
Each genetic variant was tested for association with AMD using
logistic regression assuming an additive genetic model
stratified by self-described race/ethnicity (e.g., European
American, African American, Mexican American, and Asian).
Single nucleotide polymorphisms available for analysis by study
site are given in Supplementary Table S1. All models were
adjusted for site of ascertainment (model 1, minimally
adjusted). Models 2 and 3 were adjusted for age; sex; body
mass index (BMI); smoking status (current versus ever/never);
and HDL cholesterol, fasting (‡8 hours; model 2) or regardless
of fasting status (model 3). Participants on lipid-lowering
medications were excluded in both models 2 and 3. Asians
were represented by the SP2 cohort only in model 2 given the
lack of fasting HDL-C in the SiMES cohort.
Local analyses were conducted using data analysis and
statistical software: Stata 9.0 (StataCorp, LP, College Station,
TX, USA; ARIC); SAS v9.3 (SAS Institute, Inc., Cary, NC, USA;
CHS), SAS v9.2 (by EAGLE using the Analytic Data Research by
Email [ANDRE] portal of the CDC Research Data Center in
Hyattsville, MD, USA), and genome data analysis software
(PLINK v1.06; Harvard University, Cambridge, MA, USA; SP2/
SiMES).
After analyses were conducted locally at each site, meta-
analyses using summary statistics were carried out using a
fixed-effects, inverse-variance weighted approach implement-
ed in a metal analysis helper (METAL; University of Michigan,
Ann Arbor, MI, USA).53 Between-study heterogeneity was
tested for in METAL with the Cochran’s Q-test. Genomic
control was applied on the combined meta-analysis and not
each specific cohort analysis to avoid overcorrection of
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population stratification. Meta-analysis results were plotted
using Synthesis-View.54
All P values listed in the manuscript and tables are
uncorrected for multiple hypothesis testing. The following
Bonferroni corrected thresholds were calculated by population
based on the number of available SNPs in that population
across all study sites regardless of whether the SNP was
available at each study site: European Americans (0.05/49
SNPs) ¼ 0.0010; African Americans (0.05/47 SNPs) ¼ 0.0010;
Mexican Americans (0.05/31 SNPs)¼0.0016; and Asians (0.05/
43 SNPs) ¼ 0.0012.
RESULTS
Study Population Characteristics
The meta-analysis is composed of multiple studies within the
PAGE study (ARIC, CHS, and EAGLE) and Asian cohorts
comprised of SP2 and SiMES (Table 1). Combined, this meta-
analysis includes various racial/ethnic groups: European
Americans (830 cases and 5710 controls); African Americans
(95 cases and 1172 controls); Mexican Americans (47 cases
and 270 controls); Singaporean Chinese (21 cases and 206
controls); and Singaporean Malays (107 cases and 863
controls). All study sites ascertained both men and women.
Smoking status was defined as current versus ever/never
smoker and varied across studies (Table 1). The average BMI
was greater than 25 kg/m2 across all studies regardless of case
status, except in the ethnically Chinese population (SP2).
Replication of Previously Associated AMD Variants
in European Americans
We meta-analyzed tests of associations for up to 19 SNPs
previously associated with AMD. Among European Americans,
13 AMD SNPs were tested, and 7/13 (54%) were significant at
an uncorrected P < 0.05 in model 1 (Table 1 and
Supplementary Table S2; Fig. 1). As expected, both CFH
rs1061170 (OR ¼ 1.55; P ¼ 3.05 3 108) and ARMS2
rs10490924 (OR ¼ 1.55; P ¼ 6.36 3 106) were strongly
associated with AMD risk (Table 2) at a Bonferroni corrected P
value (P < 0.001). The genetic effect sizes estimated here were
smaller for these variants compared with previous reports with
other studies estimating risk between 2.7 and 4.6 for
heterozygotes (Fig. 2).2,3,55,56 Three additional CFH SNPs were
associated with AMD risk at P < 0.05 in European Americans:
missense rs800292 (OR ¼ 0.58; P ¼ 3.80 3 105), intergenic
rs3753394 (OR¼ 1.25; P¼ 0.03), and intronic rs6677604 (OR
¼ 0.77; P ¼ 0.04; Supplementary Table S2). The remainder of
the complement factor SNPs that were tested failed to replicate
at this liberal significance threshold. Two lipid-related variants
previously associated with AMD25,26,56 were nominally associ-
ated with AMD in European Americans: CETP rs3764261 (OR¼
1.14; P ¼ 0.04) and ABCA1 rs1883025 (OR ¼ 0.82; P ¼ 0.03).
After adjustment for age, sex, BMI, smoking status, and HDL-C
(model 3), only CFH rs1061170, ARMS2 rs10490924, and CFH
rs800292 remained significant at a Bonferroni corrected P
value (Supplementary Table S3; Supplementary Fig. S2).
Generalization of Previously Associated AMD
Variants to Diverse Populations
We consider a previously associated AMD variant to have
generalized if the same variant was associated in a different
population with the same direction of effect as observed in the
original population (in this case, European-descent popula-
tions). For Mexican Americans, only one study contributed
data toward generalization: EAGLE accessing NHANES III,
which included 47 cases and 270 controls. Among tests of
association for variants previously associated with AMD, 1/8
(12%) in model 1 was significant at an uncorrected P < 0.05 in
Mexican Americans. The association between ARMS2
rs10490924 (OR ¼ 1.63; P ¼ 0.04) and AMD in Mexican
Americans has been previously reported for EAGLE accessing
NHANES III.57 The association between ARMS2 rs10490924
and AMD in Mexican Americans is still significant (P¼ 0.05) in
this study after adjustment for model 3 covariates (Supple-
mentary Table S3). However, after strict correction for multiple
testing, none of the SNPs tested in Mexican Americans was
associated with AMD.
Among African Americans, none of the 13 previously
associated SNPs were associated with AMD in model 1 in this
population at the liberal significance threshold of P < 0.05. Of
note is the test of association between AMD and ARMS2
rs10490924. A previous report accessing only NHANES III data
consisting of 30 cases and 209 controls suggested this variant
was marginally associated with AMD in the opposite direction
compared with European Americans.57 In this meta-analysis,
the test of association was expanded to include an additional
34 cases and 582 controls from ARIC. The resulting point
estimate of the genetic effect size (OR¼ 0.83; 95% confidence
interval [CI]: 0.51–1.33) was consistent with the original
report by Spencer et al.,57 but the test of association was no
longer significant (P ¼ 0.43).
Similar to African Americans, in Asians none of the
previously associated AMD variants were associated with
AMD in model 1 in this population at a liberal significance of
P < 0.05. While CFH rs1061170 failed to generalize in terms of
statistical significance (P ¼ 0.24), the point estimate of the
genetic effect (OR¼4.43; 95% CI: 0.35–55.29) was in the same
direction as the effect sizes observed for European-descent
populations (Table 2; Figs. 1, 2).
Lipid-Associated SNPs and AMD
Given that recent GWAS have highlighted the association of
genes traditionally involved in lipid pathways as mediators of
AMD risk, we tested an additional 44 lipid-trait variants in these
diverse populations for association with AMD.26,56,58 Among
the variants associated with lipid traits that were not previously
associated with AMD in European-descent populations, only
LIPC rs261332 (model 1) was marginally associated with AMD
in European Americans at P¼ 0.052 (Table and Supplementary
Table S2; Fig. 1); LIPC rs261332 (OR¼ 0.77) was only tested in
ARIC with a total of 289 cases.
In non–European-descent populations, several lipid-associ-
ated SNPs were associated with AMD. Among 95 and 1172
African American cases and controls, respectively, 3/41 (7%)
SNPs that were previously associated with a lipid trait were
associated with AMD at the uncorrected threshold of P < 0.05
in model 1. These single nucleotide polymorphisms include
LPL rs328 (OR¼ 1.75; P¼ 0.03); TRIB1 rs6987702 (OR¼ 1.61;
P¼ 0.04); and CETP rs1800775 (OR ¼ 1.57; P¼ 0.04; Table 2
and Supplementary Table S2; Fig. 1). In Mexican Americans, 1/
29 (3%) lipid-related SNPs tested reached significance at an
uncorrected P < 0.05 (model 1). This variant was rs2338104
(KCTD10/MVK), previously associated with HDL cholesterol,
associated here with AMD (OR ¼ 1.69; P ¼ 0.02).59,60 The
associations observed for LPL rs328 and TRIB1 rs6987702 in
African Americans and KCTD10/MVK rs2338104 in Mexican
Americans remained significant after adjusting for covariates
including fasting HDL-C (Supplementary Table S3). Of the 35
lipid-associated SNPs tested in the SP2 and SiMES meta-analysis
of Asians, none of the association tests reached significance at
an uncorrected P < 0.05. After strict correction for multiple
AMD Meta-Analysis in PAGE IOVS j October 2014 j Vol. 55 j No. 10 j 6843
testing none of the lipid-associated SNPs were associated with
AMD in any population.
DISCUSSION
We tested up to 57 SNPs representing 19 previously associated
AMD variants and 38 previously associated lipid trait variants
for association with AMD in European Americans, African
Americans, Mexican Americans, and Asians. At an uncorrected
P value for multiple testing (P < 0.05), we replicated up to 54%
(7/13) of the previously reported associations for AMD tested
here in European Americans. Only one previously reported
AMD association (ARMS2 rs10490924) generalized to Mexican
Americans (model 1; Table 2), whereas none generalized to
African Americans and Asians. In contrast, several associations
were observed between lipid trait-associated variants and AMD
in African Americans and Mexican Americans.
FIGURE 1. Synthesis view plot of nominally significant (P < 0.05) meta-analysis association results for model 1 which is minimally adjusted only for
site of ascertainment, for all race/ethnicities. Statistical (P) values are represented by the colored arrows and are transformed by the –log10, with the
threshold of P¼ 0.05 marked by the red line. Colored arrows also show the direction of effect (beta). Betas, P values, and coded allele frequencies
(CAF) are plotted by race/ethnicity.
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Factors That Impact Generalization of AMD-
Associated Variants
The lack of replication and/or generalization could be due to
power. Indeed, sample sizes for non–European-descent popu-
lations were limited. For the two most strongly associated
variants observed in European Americans (rs1061170 CFH and
rs10490924 ARMS2), we had greater than 90% power to detect
published effect sizes of 2.41 and 2.94 in African Americans
and Mexican Americans, assuming an additive genetic model at
a P value of 0.05.56 Therefore, compared with the effect sizes
described in the literature for European Americans (Fig. 2), we
were generally well powered to detect previously reported
associations with these two SNPs in African Americans and
Mexican Americans. In the present study, the direction of
effect for CFH rs1061170 (OR¼1.36) in African Americans was
the same as that previously reported in European Americans
(OR ¼ 1.80–4.60; Fig. 2); however, the direction of effect for
ARMS2 rs10490924 (OR ¼ 0.83) was opposite that of
published studies of European Americans. In Mexican Amer-
icans, the direction of effect was the same for both variants as
that observed in European Americans. The consistent direction
of effect observed in Mexican Americans may represent
European admixture at or surrounding this genomic region.
However, due to the limited genetic data available in the
present study, we could not explicitly test this hypothesis. In
the Asian population, we were underpowered to detect an
association for CFH rs1061170 due to the limited number of
cases (n ¼ 8) genotyped for this particular variant; ARMS2
rs10490924 was not genotyped in this Asian population.










rs1061170 CFH 1 1.55 (1.34–1.78) þ,.,þ 3.05 3 108 C 0.37 European American
1.36 (0.91–2.04) þ,.,þ 0.13 0.38 African American
1.22 (0.70–2.13) † 0.47 0.20 Mexican American
4.43 (0.35–55.29) † 0.24 0.04 Asian
rs800292 CFH 1 0.59 (0.47–0.74) † 3.80 3 105 A 0.24 European American
0.55 (0.29–1.03) † 0.06 0.69 African American
0.89 (0.68–1.15) –,–,–,þ 0.36 0.42 Asian
rs3753394 CFH 1 1.25 (1.03–1.51) † 0.03 T 0.29 European American
1.45 (0.60–3.53) † 0.41 0.08 African American
0.97 (0.75–1.25) þ,–,þ,– 0.80 0.54 Asian
rs6677604 CFH 1 0.77 (0.61–0.97) † 0.04 A 0.22 European American
0.63 (0.31–1.28) † 0.20 0.37 African American
0.97 (0.54–1.75) –,–,þ,þ 0.92 0.05 Asian
rs328 LPL 8 0.95 (0.79–1.14) –,–,þ 0.60 G 0.10 European American
1.75 (1.06–2.91) þ,þ,þ 0.03 0.07 African American
1.30 (0.55–3.08) † 0.53 <0.01 Mexican American
rs6987702 TRIB1 8 1.01 (0.87–1.17) –,þ,. 0.93 T 0.73 European American
1.61 (1.03–2.52) þ,þ,. 0.04 0.29 African American
1.20 (0.90–1.58 þ,þ,þ,þ 0.21 0.43 Asian
rs1883025 ABCA1 9 0.82 (0.69–0.96) –,.,– 0.03 A 0.26 European American
0.87 (0.57–1.33) –,.,– 0.52 0.35 African American
0.93 (0.57–1.54) † 0.78 <0.01 Mexican American
0.40 (0.08–1.91) .,–,.,. 0.25 0.23 Asian
rs10490924 ARMS2 10 1.55 (1.29–1.81) þ,.,þ 6.36 3 106 T 0.22 European American
0.83 (0.51–1.33) þ,.,– 0.43 0.24 African American
1.63 (1.02–2.60) † 0.04 0.26 Mexican American
rs2338104 KCTD10 12 1.05 (0.92–1.20) .,–,þ 0.50 G 0.53 European American
0.86 (0.61–1.22) –,–,þ 0.40 0.74 African American
1.69 (1.08–2.64) † 0.02 0.45 Mexican American
rs261332 LIPC 15 0.77 (0.60–0.98) † 0.05 A 0.20 European American
1.11 (0.57–2.18) † 0.75 0.25 African American
0.39 (0.05–3.45) .,–,.,. 0.40 0.12 Asian
rs1800775 CETP 16 1.00 (0.87–1.16) –,.,þ 0.98 C 0.52 European American
1.57 (1.03–2.38) þ,.,þ 0.04 0.42 African American
1.13 (0.70–1.83) † 0.59 0.46 Mexican American
1.03 (0.79–1.34) þ,þ,þ,– 0.84 0.51 Asian
rs3764261 CETP 16 1.14 (1.01–1.28) þ,þ,– 0.04 T 0.33 European American
0.99 (0.71–1.40) –,þ,– 0.96 0.33 African American
0.78 (0.46–1.32) † 0.37 0.31 Mexican American
1.07 (0.74–1.53) þ,–,þ,þ 0.73 0.17 Asian
Each study site performed tests of association using logistic regression assuming an additive genetic model. Data were meta-analyzed using a
fixed-effects inverse-variance weighted approach. Results are shown for nominally significant tests at an uncorrected threshold (P < 0.05) adjusted
for site of ascertainment (model 1). Bold P values are those that met strict Bonferroni correction.
* Direction of effect is given for ARIC, CHS, and EAGLE for European Americans, African Americans, and Mexican Americans, if data are available.
Direction of effect is given for Asians for SiMES and SP2 1M, 550, and 610 platforms. Otherwise, the study site is set to missing (‘‘.’’).
† Only a single study site is represented.
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Although our study was powered to detect published effect
sizes in African Americans and Mexican Americans, these
previous estimates were based on studies of European-descent
individuals and may not be representative of the risk of AMD in
diverse populations explored here.
Differences in linkage disequilibrium could also have
adversely affected our ability to generalize associations
originally identified in European-descent populations. In this
study, we only tested the index variants reported in the
literature. The index variants are often not the causal or
functional variant; rather, the index variant is in linkage
disequilibrium (LD) or ‘‘tags’’ the unknown functional variant.
Failure to genotype or target the functional or causal variant
can potentially reduce power to detect the association if the
genotyped variant is not in perfect LD with the true functional
or causal variant.
Fine-mapping or GWAS data are not available for this study;
therefore, LD patterns cannot be directly compared across the
study populations described here. However, examination of LD
patterns in HapMap III for Europeans (CEU), African Americans
in Southwest US (ASW), Mexican Americans (MEX), and Han
Chinese in Beijing (CHB) suggests that LD differs in AMD-
associated genomic regions across populations as expect-
ed.61,62 For example, in the region of ARMS2 (rs10490924),
Haploview63 plots of CEU (Supplementary Fig. S2a) show
rs10490924 in perfect LD (r2 ¼ 1) or near perfect LD (r2 >
0.90) with four intronic SNPs (rs3750848, rs3750847,
rs2284665, rs932275) in an approximately 17-kb region. These
single nucleotide polymorphisms are also in perfect/near
perfect LD with rs10490924 in HapMap MEX (Supplementary
Fig. S2c). However in HapMap ASW (Supplementary Fig. S2b),
neither rs2284665 nor rs932275 are in perfect LD although
they are still correlated to rs10490924 (r2¼ 0.47 and r2¼ 0.70,
respectively). In HapMap CHB, rs10490924 is again in perfect
LD with rs3750848 and rs3750847 and high LD with
rs2284665 and rs932275 (r2¼0.86 and r2¼0.63, respectively).
Many other variants upstream of rs10490924 are in moderate
LD (r2 > 0.25) in CEU and MEX. There is less evidence of LD
present in ASW and CHB. Generalization of rs10490924 in
Mexican Americans (Table 2) but not in African Americans in
our study coupled with LD patterns suggest that rs10490924
may not be a major factor behind AMD susceptibility in African
Americans.
Power in this study could have also been affected by
differences in allele frequencies between populations. In a
comprehensive review of estimates of CFH Y402H frequency,
four studies of CFH Y402H in African-descent populations
were identified.49,64,65 The allele frequency estimates from
these four studies range from 0.34 to 0.43, in line with our
estimate of 0.38. It is intriguing that despite a high frequency of
the risk allele similar to European-descent populations, the
prevalence of AMD in African and African-descent populations
is much lower.66 This suggests that other genetic and/or
environmental factors are at play. Of the four race/ethnicities
represented, Mexican Americans and Asians had the lowest
frequency of Y402H (0.20 and 0.04, respectively). The lower
frequency of this variant may account for at least some of the
difference in prevalence of AMD in Hispanics compared with
European-descent populations.66
Cholesteryl ester transfer protein (CETP) variant rs3764261,
which has been associated with HDL levels and AMD in
European-descent populations, was replicated in our European
American analyses (uncorrected P < 0.05).25,57,67,68 The allele
frequency for this SNP was 0.33 in our European Americans,
similar to the 0.32 and 0.31 in the African Americans and
Mexican Americans, respectively. A study by Chen et al.25
found that rs3764261 trended toward significance in a
Japanese population with a frequency of 0.22. In the present
study, the Singaporean population had a similar frequency of
0.17, but was not associated with AMD. As with CFH Y402H,
the frequency of the rs3764261 allele is similar across diverse
populations, but does not appear to contribute to AMD risk in
all populations suggesting that this variant may only be
‘‘tagging’’ the casual variant.
AMD Risk and Lipid Trait-Associated Variants
Lipid levels and lipid metabolism have been associated with
susceptibility and progression of AMD in various popula-
tions.24,69,70 The cholesteryl ester transfer protein is a plasma
glycoprotein involved in the transport and removal of
lipoproteins from blood circulation and as a component of
the reverse cholesterol transport pathway. Variants in CETP
have been found to cause an increase or decrease in blood lipid
levels with corresponding high or low blood levels of
CETP.71,72 This gene has been identified in various studies as
a modifier of AMD susceptibility.25,56 Our study found
nominally significant associations with CETP variants,
rs1800775 and rs3764261, in European Americans and African
Americans. These variants of CETP, along with other lipid-
FIGURE 2. Forest plots with odds ratios and confidence intervals for previously reported associations of CFH rs1061170 and ARMS2 rs10490924
compared with results for current study for European-descent populations.
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related genes in our study, were found to be nominally
significant (rs328 [LPL] and rs6987702 [TRIB1]) in African
Americans; and rs2338104 (KCTD10/MVK) in Mexican Amer-
icans. We observed more of these lipid-related associations in
diverse populations than the European American population
supporting the role of lipids in disease susceptibility across
diverse populations. Still, more studies are needed to elucidate
the role they play in risk of AMD due to limited sample size.
Overall Limitations and Strengths
The major limitation for the PAGE study of age-related macular
degeneration was small sample size. As expected, the
European-descent samples (~6500) constitute the largest
population. Sample sizes for African Americans, Mexican
Americans, and Asians were smaller, which adversely impacted
power to detect associations. Sample size was further impacted
by the fact that not all SNPs were genotyped or available in all
study populations. Also, as already emphasized, only the index
variant was genotyped in PAGE. The lack of GWAS-level or fine-
mapping data abolished our ability to examine differences in
LD in these study populations.
Despite the small sample sizes, a major strength of the
present study is the diversity of populations included. Several
large-scale studies have examined the genetic risk variants
associated with AMD in European-descent,8,57,59,73–75 Japa-
nese,25,76–78 and Chinese populations.79–82 Indeed, some of
these previous GWAS for AMD have included many of the same
European American and Singaporeans examined here. In
contrast, only a handful of limited genotyping studies have
examined various Hispanic and African American groups in
association with AMD and complement factor genes, APOE,
and ARMS2/HTRA1.58,67,83–85 Compared with previous publi-
cations, this study contributes new data beyond CFH and
ARMS2/HTRA1in African Americans and Mexican Americans.
These new data, coupled with the cumulative data collected in
European American and Asian populations highlight shared as
well as unique associations for AMD across diverse popula-
tions.
CONCLUSIONS
In summary, we have characterized the genetic architecture of
known AMD-related variants and variants in cholesterol
pathways in the three major race/ethnicities in the United
States, and Chinese and Malay individuals from Singapore.
Although limited in scope, this study has identified potential
genetic factors influencing the risk of AMD in diverse
populations. The potential exists for elucidating population-
specific causative pathways as highlighted by the presence or
lack of an association of CFH Y402H and ARMS2 A69S across
populations.
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71. Ridker PM, Paré G, Parker AN, et al. Polymorphism in the CETP
gene region, HDL cholesterol, and risk of future myocardial
infarction: Genomewide analysis among 18 245 initially
healthy women from the Women’s Genome Health Study.
Circ Cardiovasc Genet. 2009;2:26–33.
72. Chang M, Ned RM, Hong Y, et al. Racial/ethnic variation in the
association of lipid-related genetic variants with blood lipids in
the US adult population. Circ Cardiovasc Genet. 2011;4:523–
533.
73. Naj AC, Scott WK, Courtenay MD, et al. Genetic factors in
nonsmokers with age-related macular degeneration revealed
through genome-wide gene-environment interaction analysis.
Ann Hum Genet. 2013;77:215–231.
74. Holliday EG, Smith AV, Cornes BK, et al. Insights into the
genetic architecture of early stage age-related macular
degeneration: a genome-wide association study meta-analysis.
PLoS One. 2013;8:e53830.
75. Cipriani V, Leung H-T, Plagnol V, et al. Genome-wide
association study of age-related macular degeneration identi-
fies associated variants in the TNXB-FKBPL-NOTCH4 region of
chromosome 6p21.3. Hum Mol Genet. 2012;21:4138–4150.
AMD Meta-Analysis in PAGE IOVS j October 2014 j Vol. 55 j No. 10 j 6849
76. Arakawa S, Takahashi A, Ashikawa K, et al. Genome-wide
association study identifies two susceptibility loci for exuda-
tive age-related macular degeneration in the Japanese popu-
lation. Nat Genet. 2011;43:1001–1004.
77. Tanaka K, Nakayama T, Yuzawa M, et al. Analysis of candidate
genes for age-related macular degeneration subtypes in the
Japanese population. Mol Vis. 2011;17:2751–2758.
78. Goto A, Akahori M, Okamoto H, et al. Genetic analysis of
typical wet-type age-related macular degeneration and poly-
poidal choroidal vasculopathy in Japanese population. J Ocul
Biol Dis Infor. 2009;2:164–175.
79. Liu K, Chen LJ, Tam POS, et al. Associations of the C2-CFB-
RDBP-SKIV2L locus with age-related macular degeneration and
polypoidal choroidal vasculopathy. Ophthalmology. 2013;120:
837–843.
80. Wu L, Tao Q, Chen W, et al. Association between polymor-
phisms of complement pathway genes and age-related macular
degeneration in a Chinese population. Invest Ophthalmol Vis
Sci. 2013;54:170–174.
81. Tian J, Yu W, Qin X, et al. Association of genetic polymor-
phisms and age-related macular degeneration in Chinese
population. Invest Ophthalmol Vis Sci. 2012;53:4262–4269.
82. Ng TK, Chen LJ, Liu DTL, et al. Multiple gene polymorphisms
in the complement factor h gene are associated with exudative
age-related macular degeneration in Chinese. Invest Ophthal-
mol Vis Sci. 2008;49:3312–3317.
83. Nonyane BAS, Nitsch D, Whittaker JC, et al. An ecological
correlation study of late age-related macular degeneration and
the complement factor H Y402H polymorphism. Invest
Ophthalmol Vis Sci. 2010;51:2393–2402.
84. Tedeschi-Blok N, Buckley J, Varma R, et al. Population-based
study of early age-related macular degeneration: role of the
complement factor H Y402H polymorphism in bilateral but
not unilateral disease. Ophthalmology. 2007;114:99–103.
85. Tikellis G, Sun C, Gorin MB, et al. Apolipoprotein e gene and
age-related maculopathy in older individuals: the cardiovascu-
lar health study. Arch Ophthalmol. 2007;125:68–73.
AMD Meta-Analysis in PAGE IOVS j October 2014 j Vol. 55 j No. 10 j 6850
